Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 473,156
  • Shares Outstanding, K 187,018
  • Annual Sales, $ 15,450 K
  • Annual Income, $ -111,570 K
  • 60-Month Beta 0.29
  • Price/Sales 29.78
  • Price/Cash Flow N/A
  • Price/Book 5.66
Trade TSHA with:

Options Overview Details

View History
  • Implied Volatility 123.86% ( -13.34%)
  • Historical Volatility 118.18%
  • IV Percentile 27%
  • IV Rank 12.51%
  • IV High 961.69% on 06/28/23
  • IV Low 4.07% on 12/19/23
  • Put/Call Vol Ratio 0.20
  • Today's Volume 147
  • Volume Avg (30-Day) 204
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 2,458
  • Open Int (30-Day) 5,703

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.12
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +60.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.14 +9.56%
on 04/19/24
3.43 -31.49%
on 03/25/24
-0.90 (-27.69%)
since 03/22/24
3-Month
1.41 +66.67%
on 02/14/24
3.55 -33.80%
on 03/01/24
+0.88 (+59.86%)
since 01/24/24
52-Week
0.50 +370.00%
on 06/26/23
3.89 -39.59%
on 09/05/23
+1.68 (+252.96%)
since 04/24/23

Most Recent Stories

More News
3 Growth Stocks That Could Go Parabolic in 2024

These innovation-oriented companies could take flight this year.

ABCL : 3.90 (-1.76%)
CERS : 1.6600 (-1.19%)
TSHA : 2.35 (-7.11%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Taysha Gene Therapies, Inc. (NASDAQ: TSHA) for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

TSHA : 2.35 (-7.11%)
2 Healthcare Stocks That More Than Tripled Recently. Can They Keep Climbing?

These highly volatile stocks recently rocketed higher, but what are the chances that they'll be able to provide further gains?

CGC : 8.97 (-0.66%)
TSHA : 2.35 (-7.11%)
S&P Futures Tick Lower As Investors Await Fed Rate Decision, Snap Plunges on Weak Outlook

March S&P 500 futures (ESH23) are trending down -0.41% this morning after three major U.S. benchmark indices finished the regular session higher as market participants weighed up economic data and a slew...

ESH23 : 3,957.05s (-0.09%)
GM : 45.08 (-0.04%)
PHM : 112.26 (-0.44%)
SNAP : 11.08 (-2.72%)
HUSQB.S.DX : 84.860 (+1.92%)
WDC : 69.55 (-0.53%)
EA : 128.14 (+0.79%)
AMD : 151.74 (-0.35%)
JSPR : 22.03 (-0.36%)
TSHA : 2.35 (-7.11%)
Taysha Gene Therapies, Inc. (TSHA) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Taysha Gene Therapies, Inc. (TSHA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

TSHA : 2.35 (-7.11%)
Taysha Gene Therapies (NASDAQ: TSHA) Receives $50 Million Strategic Investment From Astellas Pharma to Develop AAV-Based Gene Therapeutics

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a biotechnology company that is focused on developing gene therapies to treat monogenic

TSHA : 2.35 (-7.11%)
Pre-Market Brief: Stocks Move Higher on Hopes of Fed Pivot

December S&P 500 futures (ESZ22) are trending up +0.03% this morning after three major US benchmark indices notched their second day of gains as soft economic data suggested the effects of the Fed's aggressive...

ESZ22 : 3,871.47s (-0.66%)
SAP.D.DX : 172.380 (-1.81%)
WEBR : 8.12 (unch)
TSHA : 2.35 (-7.11%)
MULN : 3.77 (+38.10%)
ADTN : 4.75 (-0.63%)
ZION : 42.17 (+1.01%)
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs

- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha's...

TSHA : 2.35 (-7.11%)
Taysha Gene Therapies, Inc. (TSHA) Q2 2022 Earnings Call Transcript

TSHA earnings call for the period ending June 30, 2022.

TSHA : 2.35 (-7.11%)
Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential (SNAP), a definitive clinical...

TSHA : 2.35 (-7.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104...

See More

Key Turning Points

3rd Resistance Point 2.71
2nd Resistance Point 2.62
1st Resistance Point 2.49
Last Price 2.35
1st Support Level 2.27
2nd Support Level 2.18
3rd Support Level 2.05

See More

52-Week High 3.89
Fibonacci 61.8% 2.60
Last Price 2.35
Fibonacci 50% 2.20
Fibonacci 38.2% 1.79
52-Week Low 0.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar